Head to head
Dulaglutide against Liraglutide
Weekly against daily inside the GLP-1 class, tested directly in a phase 3 non-inferiority trial. This is the pair where the dosing schedule, not the effect size, turned out to be the difference.
Column A
DulaglutideDulaglutide (GLP-1 receptor agonist)
A once-weekly GLP-1 receptor agonist for type 2 diabetes with demonstrated cardiovascular risk reduction.
Column B
LiraglutideLiraglutide (GLP-1 receptor agonist)
A once-daily GLP-1 receptor agonist and the first GLP-1 approved specifically for obesity, with proven cardiovascular benefit.
These two were tested against each other directly
A head to head trial, not two separate records compared by us.
HbA1c fell 1.42 percent on dulaglutide and 1.36 percent on liraglutide, a treatment difference of 0.06 percentage points (95% CI 0.19 to 0.07), meeting non-inferiority. Nausea affected 20 percent against 18 percent, diarrhoea 12 percent in both, and discontinuation for adverse events 6 percent in both groups. No severe hypoglycaemia was reported in either arm.
What the trial was
Phase 3, randomised, open-label, parallel-group non-inferiority trial at 62 sites in nine countries. 599 adults with type 2 diabetes inadequately controlled on at least 1500 mg metformin daily, HbA1c between 7.0 and 10.0 percent and BMI 45 or below, randomised to once-weekly dulaglutide 1.5 mg or once-daily liraglutide 1.8 mg. Primary outcome was non-inferiority for HbA1c change at 26 weeks with a margin of 0.4 percentage points. Nobody was masked.
What the authors concluded
The authors conclude that once-weekly dulaglutide is non-inferior to once-daily liraglutide for HbA1c reduction, with a similar safety and tolerability profile.
Where this result is weak
Non-inferiority is not superiority and it is not equivalence: the trial was designed to show dulaglutide was not meaningfully worse, and a 0.4 point margin is what defines meaningfully. Open-label, 26 weeks, 599 people, HbA1c rather than any clinical event, and funded by Eli Lilly, which makes dulaglutide. It enrolled people already on metformin, so it does not speak to either drug used first line or used for weight loss without diabetes.
Side by side, on the facts we can check
| Attribute | Dulaglutide | Liraglutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Trulicity) | FDA-approved (Victoza for T2D; Saxenda for weight management) |
| Half-life | ~5 days | ~13 hours |
| Molecular weight | ~59,700 Da | 3,751.2 Da |
| Mechanism | Activates the GLP-1 receptor to enhance glucose-dependent insulin release, suppress glucagon, and slow gastric emptying. | Activates the GLP-1 receptor to increase glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. |
| Human studies cited | 2 | 2 |
| Legal status, US | FDA-approved, prescription only | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Dulaglutide and Liraglutide?
Dulaglutide: A once-weekly GLP-1 receptor agonist for type 2 diabetes with demonstrated cardiovascular risk reduction. Liraglutide: A once-daily GLP-1 receptor agonist and the first GLP-1 approved specifically for obesity, with proven cardiovascular benefit.
Which has stronger research evidence, Dulaglutide or Liraglutide?
This database does not grade compounds. It counts what was run in people: 2 of the 2 studies cited on the Dulaglutide profile were human work, against 2 of 2 for Liraglutide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Dulaglutide and Liraglutide FDA-approved?
Dulaglutide: FDA-approved (Trulicity). Liraglutide: FDA-approved (Victoza for T2D; Saxenda for weight management).
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.